At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 171 enrolled
Drug / intervention
AC-3933 +2 moredrug
Likely dose
AC-3933 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Assessing the Efficacy and Safety of AC-3933 Tablets Twice Daily in Adults With Mild to Moderate Alzheimer's Disease
In Brief
A Phase 2 clinical trial evaluating AC-3933 and Sugar Pill for Alzheimer's Disease. Completed, enrolled 171 participants across 34 sites.
Detailed Summary
The purpose of this study is to investigate efficacy and safety of different doses of AC-3933 in patients with mild to moderate Alzheimer's Disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2006
First PostedAug 2006
Primary CompletionSep 2008
TodayJul 2026
First PostedAug 3, 2006
Enrollment StartFeb 1, 2006
Primary CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 19.9 years ago
Interventions
AC-3933drug
5mg twice daily
AC-3933drug
AC-3933, 20 mg twice daily
Sugar Pillother
Sugar Pill twice daily